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PURPOSE: Metabolic syndrome is an important risk factor for cardiovascular disease. Adipokines interfere with insulin action
and endothelial cell function. We investigated the relationship among adipokines, metabolic factors, inflammatory markers, and
vascular reactivity in obese subjects with metabolic syndrome and lean controls.
METHODS: Cross-sectional study of 19 obese subjects with metabolic syndrome and 8 lean volunteers evaluated as controls.
Vascular reactivity was assessed by venous occlusion pletysmography measuring braquial forearm blood flow (FBF) and vascular
resistance (VR) responses to intra-arterial infusions of endothelium-dependent (acetylcholine-Ach) and independent (sodium
nitroprusside-SNP) vasodilators. Blood samples were obtained to evaluate C reactive protein (CRP), plasminogen activator inhibitor
1 (PAI-1), fibrinogen, adiponectin, resistin, and lipid profile. Patients were classified with regard to insulin resistance through the
HOMA-IR index.
RESULTS: PAI-1, CRP and fibrinogen were higher and adiponectin was lower in metabolic syndrome subjects compared to
controls. Metabolic syndrome subjects had impaired vascular reactivity. Adiponectin and PAI-1 were associated with insulin,
HOMA-IR, triglycerides, and HDLc; and resistin with CRP. Adiponectin was associated with VR after Ach in the pooled group
and resistin with D FBF after Ach in the metabolic syndrome group.
CONCLUSION: Metabolic syndrome subjects exhibited low levels of adiponectin and high levels of CRP, fibrinogen, and PAI-
1. Adiponectin and PAI-1 correlated with insulin resistance markers. Adiponectin and resistin correlated with vascular reactivity
parameters. An adipocyte-endothelium interaction might be an important mechanism of inflammation and vascular dysfunction.
KEYWORDS: metabolic syndrome. Adipokines. Vascular reactivity. Inflammation markers. Venous occlusion plethysmography.
INTRODUCTION
Metabolic syndrome (MetSyn) comprises an array of
cardiovascular risk factors such as abdominal obesity,
dyslipidemia, hypertension, and impaired glucose tolerance.
Insulin resistance (IR) and/or increased abdominal (vis-
ceral) obesity have been suggested as potential ethiological
factors. Insulin resistance has negative effects on arterial
and arteriolar function throughout the body.1 In addition to
the link between IR and the development of type 2 diabe-
tes, IR-associated dysfunction of resistance vessels is re-
lated to arterial hypertension and vascular occlusive dis-
eases, such as myocardial infarction and stroke.2,3 The un-
derlying mechanism of vascular dysfunction, at the en-
dothelium and smooth muscle levels, appears to be second-
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ary to excessive generation of reactive oxygen species
(ROS), a process denominated oxidative stress. Other fac-
tors, such as increased production of vasoconstrictive
agents, also seem to restrict the dilator responses. The un-
derlying cause of augmented ROS availability is not com-
pletely understood, but vascular inflammatory processes
appear to be involved. Increasing evidence has associated
insulin resistance with subclinical inflammation involving
cytokines derived from adipose tissue.4 Metabolic syndrome
has also features of a pro-thrombotic state, consisting of
increased levels of 3 clotting factors (tissue factor, factor
VII, and fibrinogen) as well as inhibition of the fibrino-
lytic pathway with increased plasminogen activator inhibi-
tor 1 (PAI-1) and decreased tissue plasminogen activator
activity.5
Adipose tissue is not an inert storage depot, but rather
a tissue actively secreting a variety of bioactive substances,
known as adipokines, with autocrine, paracrine, and endo-
crine actions that probably contribute to the increased risk
of type 2 diabetes and cardiovascular disease. Adiponectin,
a newly found adipose tissue-specific collagen-like protein,
has been noted as an important antiatherogenic and anti-
inflammatory protein.6,7 On the other hand, resistin, also
produced by the adipose tissue, has been identified in sev-
eral others tissues.8 More recently, it has been found in
monocytes and is suggested to be intrinsically related to
the inflammatory process.9 Resistin antagonizes insulin ac-
tion and has been shown to impair glucose metabolism in
wild-type mice. Increased levels of resistin mRNA have
been detected in genetic and diet-induced obesity models,10
although in humans there is uncertainty about the relation-
ships between resistin, body fat mass, and insulin resist-
ance markers.11 PAI-1, also secreted by adipocytes, is as-
sociated with increased cardiovascular events in diabetic,
obese, and insulin-resistant subjects.12-14
To elucidate the relationship among adipokines, inflam-
mation, IR, and endothelial function, we performed a cross-
sectional study comparing obese subjects with metabolic
syndrome to lean controls.
SUBJECTS AND METHODS
The present study, approved by the local Ethical Com-
mittee, included 19 nonsmoking subjects with MetSyn and
8 healthy volunteers. The general characteristics of both
groups are described in Table 1. All subjects were selected
at the Cardiometabolic Clinic for outpatient care at the
State University of Rio de Janeiro. All of them signed an
informed consent form approved by the Ehics Committee.
At the first clinical visit, they were subjected to a com-
plete clinical examination, went through a 10 to 12 h fast-
ing lipid profile and a 75-g oral glucose tolerance test. All
subjects were found positive for at least 3 criteria for
MetSyn according to NCEP-ATPIII.15 The same trained
examiner collected anthropometric measurements twice:
waist circumference at its smallest point with the abdomen
relaxed, hip circumference at the widest part at the gluteal
region and weight using a digital scale (Filizola, Rio de
Janeiro, RJ-Brazil). Blood pressure (BP) was also meas-
ured twice after a five-minute rest in the supine position
using an automated apparatus (Multiparameter patient
monitor - Lifewindow LW6000, Digicare Biomedical Tech-
nology, West Palm Beach, WA-USA). Subjects with hyper-
tension were instructed not to stop taking their anti-hyper-
tensive medication. None was using angiotensin-convert-
ing enzyme blockers, angiotensin II antagonists or choles-
terol lowering drugs. Subjects were excluded for any of the
following reasons: diabetes mellitus type 2, smoking habit,
coronary heart disease or any major active medical issues.
VASCULAR REACTIVITY TESTS
We performed venous occlusion plethysmography af-
ter intra-arterial infusions of endothelium-dependent (Ach)
and independent (SNP) vasodilators, an accurate technique
to study vascular reactivity in humans, which indirectly as-
sess endothelial function. Forearm blood flow (FBF) and
vascular resistance (VR) responses to intra-arterial infusions
of Ach and SNP were analyzed. This study was performed
in the morning period after a 8 to 10-hour overnight fast
and in a temperature controlled room (20-22°C). A 27-
gauge spinal needle (Becton, Dickinson Ind Cirurgicas
Ltda, Juiz de Fora, MG-Brazil) was inserted into the left
Table 1 - General characteristics of control and metabolic
syndrome (MetSyn) groups
 MetSyn Control P value
n = 19 n = 8
Age (years) 40.8 ± 9.4 25.7 ± 3.9 < 0.001
Gender (male/female) 7/12 4/4 ns
Weight (kg) 102.5 ± 16 62.4 ± 12.8 < 0.001
BMI (kg/m2) 37.6 ± 6.30 21.6 ± 2.1 < 0.001
Waist circumference(cm)
women 106.5 ± 9.6 64.5 ± 5.2 < 0.001
men 105.4 ± 9.4 83.2 ± 6.4 < 0.001
Waist-hip ratio
women 0.90 ± 0.006 0.71 ± 0.004 < 0.001
men 0.97 ± 0.007 0.86 ± 0.004 < 0.001
Systolic blood pressure 150.0 ± 16.6 115.1 ± 11.4 < 0.001
(mm Hg)
Diastolic blood pressure 86.9 ± 9.6 71.0 ± 10.7  0.001
(mm Hg)
MetSyn: metabolic syndrome group; BMI: body mass index; ns=not
significant
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brachial artery, anterior to the elbow, under sterile condi-
tions and local anesthesia. Baseline measurements of FBF,
BP and heart rate were obtained after catheter insertion fol-
lowed by a 20-minute rest. A mercury-filled silastic strain-
gauge was placed on the upper third of the forearm in the
point of maximal circumference. The arm collecting cuff
pressure was 40 mm Hg and the wrist cuff occlusion pres-
sure was 200 mm Hg. Wrist cuff was inflated 1 minute be-
fore each flow measurement to avoid hand shunt. By block-
ing venous efflux with the upper arm cuff, the slope of
change in forearm volume expresses FBF. Blood pressure
was measured noninvasively simultaneously in the right arm
at each period. Baseline blood flow was recorded after a
20-minute infusion of saline at a rate of 0.8 mL/minute de-
livered by a Harvard pump (Harvard Apparatus Inc, South
Natick, Massachusetts-USA). Ach and SNP were infused
for 5 minutes each at progressive doses: 7.5, 15, and 30
mg/minute and 2, 4, and 8 mg/minute, respectively. Blood
flow was measured during the last 2 minutes for each dose
and was recorded for 10 s in every 15 s. There was a 20-
minute interval between each drug infusion. Forearm vas-
cular resistance (VR), expressed in arbitrary units, was cal-
culated by dividing mean BP by FBF for each recorded pe-
riod. The plethysmograph (Hokanson EC6, D.E.
Honkanson Inc, Bellevue, WA, USA) was connected to an
analog-to-digital converter (8SP, AD Instruments Pty Ltd,
Castle Hill-Australia) and the data was analyzed by Power
Lab software on an IBM PC compatible.
LABORATORY ANALYSIS
Fasting plasma glucose, total cholesterol, triglycerides,
and HDL-cholesterol (HDLc) were measured by enzyme-
colorimetric GOD-PAP automated method (Modular
Analytics PP, Roche). LDL cholesterol was calculated by the
Friedwald equation. Fasting plasma insulin, C-reactive pro-
tein (CRP), and fibrinogen were measured by automated
chemoluminiscence (coefficient of variation-CV 4.68%),
immunoturbimetric (CV 2.14%), and coagulometric (CV
1.6%) methods, respectively. Blood samples were centri-
fuged and stored at -70oC for further analysis of adipokines.
Adiponectin (Adp), resistin, and PAI-1 were measured by
human serum adipokine (panel A, Lincoplex kit CAT-
HADK1-61K-A, Linco Research-St Charles, Missouri -
USA). The intra and inter-assay CV were 6.11% and 13.2%,
7.26% and 9.12%, and 4.37% and 20.8%, respectively.
HOMA-IR was calculated to assess insulin resistance.16
STATISTICAL ANALYSIS
Data were analyzed using SPSS 10.0 software for Win-
dows (SPSS, Chicago, IL-USA). Comparisons between
groups were performed by independent samples Student t
test and Mann Whitney tests, as indicated. Correlation
analysis was performed by Spearman rank order test. All
group data are reported as mean ± SD, except for non-nor-
mal variables. Logarithmic transformation was used to nor-
malize non-normally distributed variables. Significant dif-
ferences were assumed when P < 0.05.
RESULTS
The differences in laboratory parameters are displayed
in Table 2. As expected, MetSyn group had higher fasting
plasma glucose, insulin and HOMA-IR. Adiponectin was
lower, whereas PAI-1, CRP and fibrinogen were higher in
the MetSyn group compared to the control group. Resistin
values were not different between groups.
In the pooled group, adiponectin was associated with
insulin (r = -0.50, P = 0.009), HOMA-IR (r = -0.41, P =
0.04), triglycerides (r = -0.44, P = 0.02), and HDLc (r =
0.49, P = 0.01). PAI-1 was associated with glucose (r =
0.67, P < 0.001), insulin (r = 0.68, P < 0.001), HOMA-IR
(r = 0.69, P < 0.001), triglycerides (r = 0.53, P = 0.02),
CRP (r = 0.39, P = 0.004), and HDLc (r = -0.55, P = 0.003)
in the pooled group. In the MetSyn group, PAI-1 was as-
sociated with glucose (r = 0.53, P = 0.01) and HOMA-IR
(r = 0.50, P =0.02). Resistin was associated with CRP (r =
0.42, P = 0.02) only in the MetSyn group.
The MetSyn group had impaired endothelium-depend-
ent and independent vasodilation compared to the control
Table 2 - Laboratory measurements in control and metabolic
syndrome (MetSyn) groups
 MetSyn Control P value
n = 19 n = 8
Glucose (mmol/l) 5.43±0.73 4.71±0.47 0.01
2h post-load glucose 7.7±1.94 5.73±0.55 0.001
(mmol/l)
Insulin (mUI/ml) 14.4±4.6 4.1±1.7 <0.001
HOMA-IR 3.4±1.2 1.0±0.4 <0.001
Total Cholesterol (mmol/l) 5.12±0.86 4.71±1.7 0.26
LDLc (mmol/l) 3.29±0.81 2.79±0.56 0.12
HDLc (mmol/l)
women 1.13±0.37 1.85±0.31 0.001
men 1.10±0.18 1.44±0.15 0.001
Triglycerides (mmol/l) 1.81±0.81 0.61±0.25   <0.001
CRP (mg/dl) 1.0 [0.5-2.0] 0.3 [0.2-0.45] 0.002
Fibrinogen (mmol/l) 3.04±0.76 2.40±0.34 0.04
Adiponectin (mg/ml) 9.5 [3.7-14.2] 19.5 [8.6-53.4] 0.03
Resistin (ng/ml) 18.9±4.8 17.2±2.2 0.36
PAI-1 (ng/ml) 25.9±6.6 14.3±4.3 <0.001
MetSyn: metabolic syndrome group; CRP: ultra sensitive C-reactive protein;
PAI-1: plasminogen activator inhibitor-1. * Data are expressed by mean ±
SD or median [IQR]
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group (Figures 1 and 2). No association could be found be-
tween PAI-1 and vascular reactivity measurements in both
groups. Adiponectin was associated with DVR after Ach
(r =0.39, P = 0.05) in the whole group, although after ad-
justments to metabolic parameters, this relationship was not
significant any more. In the MetSyn group, resistin was as-
sociated with D FBF after Ach (r = -0.47, P = 0.04), but
again, after adjustment to CRP, this relationship disap-
peared (Figures 3 and 4).
DISCUSSION
In a previous study17 we have shown that endothelial
dysfunction correlates with markers of obesity. In this study,
we show that subjects with MetSyn exhibited impaired en-
dothelium-dependent and independent vasodilation re-
sponses compared to the control group, as has already been
shown in other studies in obese and type 2 diabetic sub-
jects,18,19 and is considered a risk factor for future cardio-
vascular ischemic events.20 There is increasing evidence that
new cases of cardiovascular diseases are closely associated
with increased prevalence of insulin resistance and type 2
diabetes due to excessive weight and sedentary lifestyle.21,22
The convergence between insulin resistance and inflamma-
tion in the pathogenesis of atherosclerotic coronary disease
has been recognized over the past decade, 4,23 but the exact
mechanism by which excessive adiposity causes both in-
sulin resistance and vascular dysfunction is not completely
understood. Much of the recent work on obesity has high-
lighted the key role of adipose tissue as an endocrine or-
gan secreting a large number of substances that mediate
vascular and metabolic complications of obesity.
Resistin, as suggested by its name, should be related
to insulin resistance, but a lot of controversy surrounds its
exact biological role in humans. Even without significant
differences between the two groups studied, we were able
Figure 1 - Vascular resistance decrement (%) after Ach and SNP infusion in
subjects with MS (·) and controls (²%). (*P <0.05 intergroup)
Figure 2 - Forearm blood flow increment (%) after Ach and SNP infusion in
subjects with MS(·) and controls(²%). (*P <0.05 intergroup)
Figure 3 - Relationship between vascular resistance decrement (%) after
Ach and adiponectin level in the pooled group
Figure 4 - Relationship between forearm blood flow increment (%) and
resistin level in the pooled group
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to show an inverse relationship between resistin and en-
dothelium-dependent vasodilation in the MetSyn group. To
our knowledge, this is the first study demonstrating this re-
lationship in humans. Verma and co-workers24 reported, for
the first time, that human recombinant resistin exerted di-
rect effects on cultured endothelial cells, promoting
endotelin-1 release and upregulating adhesion molecules
and cytokines, possibly a link between this adipokine and
vascular dysfunction. Other authors have shown that resistin
can cause endothelial dysfunction in porcine coronary ar-
teries through oxidative stress and down-regulation of en-
dothelial nitric oxide synthase25 and that it can induce hu-
man aortic smooth muscle cells proliferation.26
We could not demonstrate a difference in resistin lev-
els between the two groups and any relationship between
resistin and IR markers. The analysis of several published
studies show conflicting results, some demonstrating a close
relationship between resistin and insulin resistance27 while
many others arrive at the opposite conclusion.28-30 The posi-
tive correlation between resistin and CRP found in this
study and also in others,31-33 suggests a direct
proinflammatory role of resistin that might be involved in
the inflammatory vascular process.34 In contrast to what was
found in rodents, human resistin is expressed primarily in
inflammatory cells,9 and its expression is markedly in-
creased by treatment with endotoxin and proinflammatory
cytokines in vitro.35 At cellular level, resistin has been
shown to exert pro-inflammatory properties by up-regulat-
ing cytokines, probably via the NFk-B payhway.36 We found
that resistin was associated with CRP and endothelial-de-
pendent vasodilation only in MetSyn group, with higher
CRP and lower vasodilation capacity. When adjustment for
CRP was done, the relationship between resistin and en-
dothelial-mediated vasodilation disappeared. Considering
the expression of resistin by mononuclear cells and assum-
ing that obesity and MetSyn are states of low-grade inflam-
mation, resistin may indeed represent a molecular link be-
tween metabolic signals, inflammation, and vascular dys-
function. Remarkably, Reilly and co-workers31 showed, in
a large study of 879 humans at high risk for coronary
atherosclerosis, the relationship between resistin and diverse
inflammatory markers, as well as with coronary atheroscle-
rosis.
A positive association between PAI-1 and insulin resist-
ance markers has been shown by several studies in insu-
lin-resistant, obese and nonobese subjects.12-14 We also dem-
onstrated correlations between PAI-1, insulin resistance,
and inflammatory markers. Chronic inflammation of the
vascular wall shifts haemostatic mechanisms in favor of
thrombosis. The possible mechanisms involved are en-
hanced clotting process, impaired fibrinolysis capacity and
decreased natural anticoagulant pathways.35-38 C-reactive
protein and other inflammatory mediators can down-regu-
late the protein C and thrombomodulin receptors of en-
dothelial cells. In response there is an increase in cytokine
expression and endothelial cell injury, creating a vicious
cycle.37 Therefore, factors of haemostatic and fibrinolytic
systems could be directly linked to insulin-resistance syn-
drome or be a reflection of endothelial cell activation and
chronic low-grade inflammation.
Plasma levels of adiponectin were reduced in MetSyn
group compared to the control group, which is in accord-
ance to various studies showing reduced adiponectin lev-
els in obese, diabetic, coronary heart disease, and hyper-
tensive subjects.39-41 There was an inverse correlation be-
tween adiponectin and insulin-resistance markers in the
whole group. The exact mechanism underlying the ob-
served association between adiponectin and insulin is pres-
ently unknown. In rhesus monkeys, the hyperinsulinemic-
euglycemic clamp revealed a positive correlation between
adiponectin and glucose uptake and, longitudinally, plasma
adiponectin decreased in parallel to the progression of in-
sulin resistance.42 In in vitro and animal studies, insulin
enhances adiponectin secretion,43,44 suggesting that
adiponectin secretion might be disturbed in the insulin-re-
sistance states. Indeed, the administration of recombinant
adiponectin in lipoatrophic mice caused a reversal of in-
sulin resistance.45
In this cross-sectional study, we only found a tendency
for correlation between adiponectin and endothelial de-
pendent-vasodilation in the whole group, although this as-
sociation disappeared after adjusting to metabolic param-
eters. There are several studies showing that adiponectin
favorably affects endothelial function and vascular
homeostasis.45-47 Although there is evidence of direct effects
of adiponectin on endothelial cells, the lack of correlation
after adjustments to metabolic parameters in our sample
does not confirm it. In human studies, the relationship be-
tween adiponectin and endothelial function has been dem-
onstrated in obese, type 2 diabetic, hypertensive subjects
and in healthy subjects.48-51 We found that adiponectin was
indeed decreased in subjects with MetSyn who also dem-
onstrated an impaired endothelial-dependent vasodilation.
The absence of correlation with vascular reactivity in
MetSyn group could eventually be explained by our small
sample size. Adiponectin might have a protective role in
vascular function and high levels of adiponectin correlates
to less coronary heart events in men with and without dia-
betes.52,53 Further larger studies are needed to address
whether interventions that increase adiponectin levels can
improve endothelial function and reduce cardiovascular
events.
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This is the first study showing a relationship between
resistin and vascular reactivity in MetSyn subjects, although
it has some limitations due its small sample, but also be-
cause the comparison of groups was not matched by age,
and because it was not possible to separate subgroups.
In conclusion, adiponectin and PAI-1 correlated with
insulin-resistance markers, but resistin did not. In contrast
with the initial studies connecting resistin to IR, our re-
sults are in line with others suggesting a proinflammatory
role of resistin interfering with vascular function. An
adipocyte-endothelium interaction may be an important
mechanism of inflammation and vascular dysfunction lead-
ing to increased cardiovascular disease in obesity. However,
the exact mechanism linking resistin and adiponectin to the
pathogenesis of obesity-induced insulin resistance and car-
diovascular disease deserves further studies.
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RESUMO
Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos
AF, Geloneze B et al. Relação entre as adipocinas, infla-
mação e reatividade vascular em controles magros e paci-
entes obesos com síndrome metabólica. CLINICS.
2006;61(5):433-40.
A Síndrome Metabólica é um importante fator de risco para
doenças cardiovasculares. As adipocinas interferem com a
ação da insulina e com a função endotelial.
OBJETIVO: Investigar a relação entre adipocinas, fato-
res metabólicos, marcadores inflamatórios e reatividade
vascular para inferência da função endotelial em pacien-
tes obesos e controles magros.
MATERIAL E MÉTODO: Estudo transversal de 19 pa-
cientes obesos com Síndrome Metabólica e 8 controles
magros. A reatividade vascular foi avaliada pela
pletismografia de oclusão venosa medindo o fluxo
sangüíneo da artéria braquial e sua resistência vascular a
partir de infusões intra-arteriais de vasodilatadores
endotélio-dependente (acetilcolina) e endotélio-independen-
te (nitroprussiato de sódio). Foram também avaliados no
sangue a proteína C reativa (PCR), o inibidor do ativador
do plasminogênio 1 (PAI-1), fibrinogênio, adiponectina,
resistina e o perfil lipídico. Os pacientes foram classifica-
dos quanto à resistência insulínica pelo índice HOMA-IR.
RESULTADO: PAI-1, PCR e fibrinogênio apresentaram va-
lores mais altos e a adiponectina mais baixos para os pacien-
tes com Síndrome Metabólica do que com os controles. Pa-
cientes com Síndrome Metabólica apresentaram prejuízo da
reatividade vascular. A adiponectina e PAI-1 estiveram asso-
ciadas à insulina, HOMA-IR, triglicerídeos e HDLc; e resistina
com o PCR. Adiponectina esteve associada com a resistência
vascular e a resistina com o fluxo sangüíneo depois da
acetilcolina em pacientes com Síndrome Metabólica.
CONCLUSÃO: Pacientes com Síndrome Metabólica exi-
biram baixas concentrações sangüíneas de adiponectina e
altos níveis de PCR, fibrinogênio e PAI-1. Adiponectina e
PAI-1 correlacionaram com os marcadores da resistência
insulínica. Adiponectina e resistina correlacionaram com
a reatividade vascular. A interação adipócito-endotélio
vascular pode ser um importante mecanismo de inflama-
ção e disfunção vascular.
UNITERMOS: Síndrome Metabólica. Adipocinas.
Reatividade vascular. Marcadores inflamatórios.
Pletismografia de oclusão venosa.
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